Journal of Law, Medicine and Ethics 41 (3):635-643 (2013)
Authors |
|
Abstract |
The pharmaceutical industry, in its marketing efforts, often turns to “key opinion leaders” or “KOLs” to disseminate scientific information. Drawing on the author's fieldwork, this article documents and examines the use of KOLs in pharmaceutical companies’ marketing efforts. Partly due to the use of KOLs, a small number of companies with well-defined and narrow interests have inordinate influence over how medical knowledge is produced, circulated, and consumed. The issue here, as in many other cases of institutional corruption, is that a few actors have accumulated the power to shape the information on which many others base their decisions. Efforts to address this corruption should focus on correcting large imbalances in the current political economy of medical knowledge. A sequestration of pharmaceutical research and development on one hand from pharmaceutical marketing on the other, though difficult to achieve, would address this and many other problems
|
Keywords | No keywords specified (fix it) |
Categories | (categorize this paper) |
DOI | 10.1111/jlme.12073 |
Options |
![]() ![]() ![]() ![]() |
Download options
References found in this work BETA
Physicians Under the Influence: Social Psychology and Industry Marketing Strategies.Sunita Sah & Adriane Fugh-Berman - 2013 - Journal of Law, Medicine and Ethics 41 (3):665-672.
Physicians Under the Influence: Social Psychology and Industry Marketing Strategies.Sunita Sah & Adriane Fugh-Berman - 2013 - Journal of Law, Medicine and Ethics 41 (3):665-672.
Ghost Management: How Much of the Medical Literature is Shaped Behind the Scenes by the Pharmaceutical Industry?Sergio Sismondo - manuscript
Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs.Donald W. Light, Joel Lexchin & Jonathan J. Darrow - 2013 - Journal of Law, Medicine and Ethics 41 (3):590-600.
Biomedical Conflicts of Interest: A Defence of the Sequestration Thesis--Learning From the Cases of Nancy Olivieri and David Healy.A. Schafer - 2004 - Journal of Medical Ethics 30 (1):8-24.
View all 9 references / Add more references
Citations of this work BETA
The Promise and Perils of Industry‐Funded Science.Bennett Holman & Kevin C. Elliott - 2018 - Philosophy Compass 13 (11).
Physicians Under the Influence: Social Psychology and Industry Marketing Strategies.Sunita Sah & Adriane Fugh-Berman - 2013 - Journal of Law, Medicine and Ethics 41 (3):665-672.
Physicians Under the Influence: Social Psychology and Industry Marketing Strategies.Sunita Sah & Adriane Fugh-Berman - 2013 - Journal of Law, Medicine and Ethics 41 (3):665-672.
Dangers of Neglecting Non-Financial Conflicts of Interest in Health and Medicine.Miriam Wiersma, Ian Kerridge & Wendy Lipworth - 2018 - Journal of Medical Ethics 44 (5):319-322.
Understanding Pharmaceutical Research Manipulation in the Context of Accounting Manipulation.Abigail Brown - 2013 - Journal of Law, Medicine and Ethics 41 (3):611-619.
View all 21 citations / Add more citations
Similar books and articles
Brightening Up: The Effect of the Physician Payment Sunshine Act on Existing Regulation of Pharmaceutical Marketing.Igor Gorlach & Genevieve Pham-Kanter - 2013 - Journal of Law, Medicine and Ethics 41 (1):315-322.
Publication Ethics and the Ghost Management of Medical Publication.Sergio Sismondo & Mathieu Doucet - 2010 - Bioethics 24 (6):273-283.
Ghost Management: How Much of the Medical Literature is Shaped Behind the Scenes by the Pharmaceutical Industry?Sergio Sismondo - manuscript
Pharmaceutical Speakers' Bureaus, Academic Freedom, and the Management of Promotional Speaking at Academic Medical Centers.Marcia M. Boumil, Emily S. Cutrell, Kathleen E. Lowney & Harris A. Berman - 2012 - Journal of Law, Medicine and Ethics 40 (2):311-325.
Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda.Paul D. Jorgensen - 2013 - Journal of Law, Medicine and Ethics 41 (3):561-570.
How Pharmaceutical Industry Employees Manage Competing Commitments in the Face of Public Criticism.Wendy Lipworth, Kathleen Montgomery & Miles Little - 2013 - Journal of Bioethical Inquiry 10 (3):355-367.
From Community to Commodity: The Ethics of Pharma‐Funded Social Networking Sites for Physicians.Amy Snow Landa & Carl Elliott - 2013 - Journal of Law, Medicine and Ethics 41 (3):673-679.
Drug Firms, the Codification of Diagnostic Categories, and Bias in Clinical Guidelines.Lisa Cosgrove & Emily E. Wheeler - 2013 - Journal of Law, Medicine and Ethics 41 (3):644-653.
Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs.Donald W. Light, Joel Lexchin & Jonathan J. Darrow - 2013 - Journal of Law, Medicine and Ethics 41 (3):590-600.
From Evidence-Based Medicine to Marketing-Based Medicine: Evidence From Internal Industry Documents. [REVIEW]Glen I. Spielmans & Peter I. Parry - 2010 - Journal of Bioethical Inquiry 7 (1):13-29.
Five Un‐Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.
Analytics
Added to PP index
2013-10-02
Total views
28 ( #371,338 of 2,411,732 )
Recent downloads (6 months)
1 ( #539,061 of 2,411,732 )
2013-10-02
Total views
28 ( #371,338 of 2,411,732 )
Recent downloads (6 months)
1 ( #539,061 of 2,411,732 )
How can I increase my downloads?
Downloads